Objective—To examine the effect of adjuvant doxorubicin
chemotherapy on outcome in dogs with highgrade
(grade 3) soft tissue sarcomas (HGSTSs).
Design—Retrospective case series.
Procedures—Medical records of dogs with HGSTSs
were reviewed. Dogs treated with surgery alone or
receiving single-agent doxorubicin chemotherapy
postoperatively were included in the study. Owners
and referring veterinarians were contacted for followup
information. Slides from histologic sections were
reviewed to confirm the diagnosis of HGSTSs. Cases
in which follow-up examination was not performed
and radiation therapy or chemotherapy other than
doxorubicin was administered were excluded.
Results—39 dogs met inclusion criteria. Twenty-one
dogs received adjuvant doxorubicin. Tumor-, patient-,
and treatment-related variables were not significantly
associated with measured outcomes including local,
metastatic, and overall disease-free intervals as well
as survival time. Overall median disease-free interval
was 724 days with a median survival time of 856 days
for all dogs.
Conclusions and Clinical Relevance—Adjuvant doxorubicin-based chemotherapy did not benefit this population of dogs with HGSTSs. Outcome for visceral HGSTSs
was similar to that of nonvisceral HGSTSs in these cases.
(J Am Vet Med Assoc 2005;227:1442–1448)